Lifecore Biomedical, Inc. De annual gross margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lifecore Biomedical, Inc. De's gross margin was 31.27% for fiscal 2025.
View full Lifecore Biomedical, Inc. De company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-05-25 | 31.27% | −1.36 pp |
| 2024 | 2024-05-26 | 32.63% | +5.53 pp |
| 2023 | 2023-05-28 | 27.10% | −8.01 pp |
| 2022 | 2022-05-29 | 35.11% | −3.49 pp |
| 2021 | 2021-05-30 | 38.60% | +13.99 pp |
| 2020 | 2020-05-31 | 24.61% | +10.08 pp |
| 2019 | 2019-05-26 | 14.53% | −0.42 pp |
| 2018 | 2018-05-27 | 14.94% | −1.92 pp |
| 2017 | 2017-05-28 | 16.86% | +2.86 pp |
| 2016 | 2016-05-29 | 14.00% | +1.87 pp |
| 2015 | 2015-05-31 | 12.13% | −0.99 pp |
| 2014 | 2014-05-25 | 13.12% | −1.09 pp |
| 2013 | 2013-05-26 | 14.21% | −2.21 pp |
| 2012 | 2012-05-27 | 16.42% | −0.46 pp |
| 2011 | 2011-05-29 | 16.87% | +2.70 pp |
| 2010 | 2010-05-30 | 14.17% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 35.34% | +7.34 pp |
| Q1 2026 | 2026-03-31 | 19.24% | −14.80 pp |
| Q3 2025 · Sep 30 | 2025-09-30 | 25.04% | +3.24 pp |
| Q4 2025 | 2025-05-25 | 38.37% | −7.22 pp |
| Q3 2025 · Feb 23 | 2025-02-23 | 28.01% | −5.31 pp |
| Q2 2025 | 2024-11-24 | 34.04% | +1.01 pp |
| Q1 2025 | 2024-08-25 | 21.81% | +10.68 pp |
| Q4 2024 | 2024-05-26 | 45.59% | +20.61 pp |
| Q3 2024 | 2024-02-25 | 33.31% | +1.10 pp |
| Q2 2024 | 2023-11-26 | 33.02% | +7.05 pp |
| Q1 2024 | 2023-08-27 | 11.12% | −14.08 pp |
| Q4 2023 | 2023-05-28 | 24.98% | −9.43 pp |
| Q3 2023 | 2023-02-26 | 32.21% | −1.65 pp |
| Q2 2023 | 2022-11-27 | 25.97% | +0.91 pp |
| Q1 2023 | 2022-08-28 | 25.20% | −7.11 pp |
| Q3 2022 | 2022-02-27 | 34.40% | +18.64 pp |
| Q2 2022 | 2021-11-28 | 33.86% | +21.81 pp |
| Q1 2022 | 2021-08-29 | 25.06% | +11.96 pp |
| Q3 2021 | 2021-02-28 | 32.31% | +21.43 pp |
| Q2 2021 | 2020-11-29 | 15.76% | +4.71 pp |
| Q1 2021 | 2020-08-30 | 12.05% | −5.11 pp |
| Q3 2020 | 2020-02-23 | 13.11% | −0.76 pp |
| Q2 2020 | 2019-11-24 | 10.88% | −2.68 pp |
| Q1 2020 | 2019-08-25 | 11.06% | −2.05 pp |
| Q4 2019 | 2019-05-26 | 17.16% | −0.43 pp |
| Q3 2019 | 2019-02-24 | 13.87% | +0.20 pp |
| Q2 2019 | 2018-11-25 | 13.56% | +1.37 pp |
| Q1 2019 | 2018-08-26 | 13.10% | −3.13 pp |
| Q4 2018 | 2018-05-27 | 17.59% | −6.56 pp |
| Q3 2018 | 2018-02-25 | 13.67% | −3.49 pp |
| Q2 2018 | 2017-11-26 | 12.18% | −1.77 pp |
| Q1 2018 | 2017-08-27 | 16.24% | +0.27 pp |
| Q4 2017 | 2017-05-28 | 24.15% | −2.01 pp |
| Q3 2017 | 2017-02-26 | 17.16% | +7.21 pp |
| Q2 2017 | 2016-11-27 | 13.95% | +1.66 pp |
| Q1 2017 | 2016-08-28 | 15.97% | +2.69 pp |
| Q4 2016 | 2016-05-29 | 26.16% | +12.27 pp |
| Q3 2016 | 2016-02-28 | 9.95% | −2.24 pp |
| Q2 2016 | 2015-11-29 | 12.29% | +0.48 pp |
| Q1 2016 | 2015-08-30 | 13.28% | +2.66 pp |
| Q4 2015 | 2015-05-31 | 13.88% | +0.54 pp |
| Q3 2015 | 2015-03-01 | 12.19% | −3.76 pp |
| Q2 2015 | 2014-11-30 | 11.81% | +0.37 pp |
| Q1 2015 | 2014-08-31 | 10.62% | −0.83 pp |
| Q4 2014 | 2014-05-25 | 13.35% | +1.18 pp |
| Q3 2014 | 2014-02-23 | 15.95% | +1.09 pp |
| Q2 2014 | 2013-11-24 | 11.44% | −4.66 pp |
| Q1 2014 | 2013-08-25 | 11.45% | −2.04 pp |
| Q4 2013 | 2013-05-26 | 12.16% | −5.64 pp |
| Q3 2013 | 2013-02-24 | 14.85% | −1.60 pp |
| Q2 2013 | 2012-11-25 | 16.10% | +0.15 pp |
| Q1 2013 | 2012-08-26 | 13.48% | −1.86 pp |
| Q4 2012 | 2012-05-27 | 17.80% | +2.32 pp |
| Q3 2012 | 2012-02-26 | 16.45% | −0.52 pp |
| Q2 2012 | 2011-11-27 | 15.95% | −0.95 pp |
| Q1 2012 | 2011-08-28 | 15.35% | −2.85 pp |
| Q4 2011 | 2011-05-29 | 15.48% | — |
| Q3 2011 | 2011-02-27 | 16.97% | — |
| Q2 2011 | 2010-11-28 | 16.90% | — |
| Q1 2011 | 2010-08-29 | 18.19% | — |
Over the last five reported fiscal years, Lifecore Biomedical, Inc. De's gross margin increased from 24.61% to 31.27%, a change of +6.66 percentage points. The latest reported quarter, Q2 2026, shows 35.34%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lifecore Biomedical, Inc. De filings at SEC.gov ↗